BioSpace News Archive

Scaling Builds on 4 Years of Research and Demonstration Efforts in California.

MilliDrop announces it has been awarded €1.9 million in non-dilutive financing from Bpifrance to accelerate the development of its blood infection diagnosis system for sepsis.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced its poster presentation of the anti-fibrogenic effects of Namodenosen in NAFLD/NASH pre-clinical data at the Hepatic Fibrosis Single Topic Conference of the American Association for the Study of Liver Diseases

Theragenics Corporation®, a medical device company serving the cancer treatment market, will provide sales and marketing for C4 Imaging’s novel, Orion™ Positive-Signal HDR MRI Lumen Marker

Concordia’s US$586.5 million private placement (the “Private Placement”) for new limited voting shares of Concordia, at a price of US$13.69 per limited voting share and representing in the aggregate approximately 87.69% of the outstanding limited voting shares of Concordia

pic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR).

Atreca, Inc. announced today the closing of an oversubscribed $125 million financing.

Strong bipartisan commitment from Congress to invest in biomedical science is fueling innovation in cancer research leading to advances in prevention and treatment

Enhanced capabilities are designed to advance immuno-therapy candidates from pre-clinical discovery through Phase III clinical trials using smaller samples of both tumor biopsies and liquid biopsies to generate data required for assessing drug efficacy.

The companies will collaborate to offer biosimilar manufacturing solutions to the global biosimilars market.